Thelin

1

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



2

1. NAME OF THE MEDICINAL PRODUCT

Thelin 100 mg film-coated tablets 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 100 mg sitaxentan sodium.

Excipients:
Also contains 166.3mg of lactose monohydrate.

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Film-coated tablet
Capsule shaped yellow-to-orange film-coated tablets, debossed with T-100 on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class 
III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in 
pulmonary hypertension associated with connective tissue disease.

4.2 Posology and method of administration

Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH. 

Thelin is to be taken orally as a dose of 100 mg once daily. It may be taken with or without food and 
without regard to the time of day.

In the case of clinical deterioration despite Thelin treatment for at least 12 weeks, alternative therapies 
should be considered. However, a number of patients who showed no response by week 12 of 
treatment with Thelin responded favourably by week 24, so an additional 12 weeks of treatment may 
be considered.

Higher doses did not confer additional benefit sufficient to offset the increased risk of adverse 
reactions, particularly liver injury (see section 4.4). 

Discontinuation of treatment
There is limited experience with abrupt discontinuation of sitaxentan sodium. No evidence for acute 
rebound has been observed.

Dosage in hepatic impairment:
Studies in patients with pre-existing liver impairment have not been conducted. Thelin is 
contraindicated in patients with elevated liver aminotransferases prior to initiation of treatment 
(> 3 x Upper Limit of Normal (ULN)) or with elevated direct bilirubin > 2 x ULN prior to initiation of 
treatment (see section 4.3).

Dosage in renal impairment:
No dose adjustment is required in patients with renal impairment.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



3

Use in children and adolescents (< 18 years).
Thelin is not recommended for use in children and adolescents below 18 years due to a lack of data on 
safety and efficacy.

Elderly patients:
No dosage adjustment is needed in patients over the age of 65 years.

Use in patients using other medicines:
The efficacy and safety of Thelin co-administration with other treatments for PAH (eg, epoprostenol, 
sildenafil, iloprost) has not been studied in controlled clinical trials. Therefore, caution is 
recommended in case of co-administration.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Mild to severe hepatic impairment (Child-Pugh Class A-C).

Elevated aminotransferases prior to initiation of treatment (aspartate aminotransferase (AST) and/or 
alanine aminotransferase (ALT) > 3 x ULN).

Elevated direct bilirubin > 2 x ULN prior to initiation of treatment.

Concomitant administration with ciclosporin A (see section 4.5).

Lactation (see section 4.6).

4.4 Special warnings and precautions for use

The efficacy of Thelin as monotherapy has not been established in patients with NYHA/WHO 
functional class IV PAH. Transfer to a therapy that is recommended at the severe stage of the disease 
(eg, epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).

Liver function:
Liver function abnormalities have been associated with PAH. Endothelin receptor antagonists, as a 
class, have been associated with liver function abnormalities.

Elevations of AST and/or ALT associated with Thelin occur both early and late in treatment, usually 
progress slowly, and are typically asymptomatic. During clinical trials, these changes were usually 
reversible when monitoring and discontinuation guidelines were followed. Liver aminotransferase 
elevations may reverse spontaneously while continuing treatment with sitaxentan sodium.

The mechanism of liver toxicity is not fully documented and it might vary between endothelin 
receptor antagonists. Appropriate care should be exercised when initiating sitaxentan in patients who 
discontinued other endothelin receptor antagonists due to liver enzyme abnormalities (see section 4.8).

Because treatment-associated elevations of AST and/or ALT are a marker for potential serious liver 
injury, liver aminotransferase levels must be measured prior to initiation of treatment and subsequently 
at monthly intervals.  If AST and/or ALT are > 3 x ULN prior to initiation of therapy, or direct 
bilirubin is > 2 x ULN, use of sitaxentan is contraindicated (see section 4.3)

Recommendations in case of treatment-emergent ALT/AST elevations:
If ALT/AST measurements rise to the following levels then changes to the monitoring or treatment are 
given:

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



4

>3 and ≤ 5 x ULN: Confirm by another liver test;  if confirmed, a decision should be made on an 
individual basis to continue or to stop Thelin administration.  Continue to monitor aminotransferases 
at least every 2 weeks.  If the aminotransferase levels return to pre-treatment values, consider 
resuming the initial treatment schedule according to the conditions described below. 

> 5 and ≤ 8 x ULN: Confirm by another liver test; if confirmed, stop treatment and monitor 
aminotransferase levels at least every 2 weeks until levels have normalised.  If the aminotransferase 
levels return to pre-treatment values, consider reintroducing Thelin according to the conditions 
described below.

>8 x ULN: treatment must be stopped and reintroduction of Thelin is not to be considered. 

If liver transferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, 
vomiting, anorexia, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in 
total bilirubin > 2x ULN, treatment should be stopped and re-introduction of Thelin is not to be 
considered.

Re-introduction of treatment:
Re-introduction of treatment with Thelin should only be considered if the potential benefits of 
treatment with Thelin outweigh the potential risks and when liver aminotransferase levels are within 
pre-treatment values. The advice of a hepatologist is recommended. Re-introduction must follow the 
guidelines detailed in section 4.2. Aminotransferase levels must then be checked within 3 days after 
re-introduction, then again after a further 2 weeks, and thereafter according to the recommendations 
above.

Pre-existing liver impairment
Studies in patients with pre-existing liver impairment have not been conducted. Thelin is 
contraindicated in patients with elevated liver aminotransferases prior to initiation of treatment 
(> 3 x ULN), or with elevated direct bilirubin > 2 x ULN prior to initiation of treatment, see section 
4.3.

Bleeding
There is an increased risk of bleeding with Thelin, mainly in the form of epistaxis and gingival 
bleeding.

Vitamin K antagonists
Thelin increases the plasma levels of Vitamin K antagonists such as warfarin, acenocoumarol and 
fenprocoumon (see section 4.5).

Drugs which inhibit Organic Anion Transporting Polypeptides (OATP)
The extent of interaction with potent OATP inhibitors (e.g. some statins, proteinase inhibitors, 
tuberculostatics) is unknown. As this could result in raised plasma levels of sitaxentan sodium, 
patients in need of the combination should be closely monitored for adverse events related to 
sitaxentan sodium (see section 4.5).

Oral contraceptive agents
Thelin increases oestrogen exposure when given concomitantly with oral contraceptive agents (see 
Section 4.5). Therefore, especially in women who smoke, there is an increased risk for 
thromboembolism.  Given a theoretical higher risk for thromboembolism, traditional concomitant use 
of vitamin K antagonists should be considered.

Pregnancy
Due to possible teratogenicity, Thelin must not be initiated in women of child-bearing potential unless 
they practise reliable contraception. If necessary, pregnancy testing should be undertaken (see Section 
4.6).

Pulmonary veno-occlusive disease (PVOD) 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



5

No data are available with Thelin in patients with pulmonary hypertension associated with pulmonary 
veno-occlusive disease. However, cases of life threatening pulmonary oedema have been reported with 
vasodilators (mainly prostacyclin) when used in those patients. Consequently, should signs of 
pulmonary oedema occur when Thelin is administered in patients with pulmonary hypertension, the 
possibility of associated veno-occlusive disease should be considered.

Haemoglobin concentration
Treatment with Thelin was associated with a dose-related decrease in haemoglobin (see section 4.8).
Most of this decrease of haemoglobin concentration was detected during the first few weeks of 
treatment and haemoglobin levels stabilized by 4 weeks of Thelin treatment. It is recommended that 
haemoglobin concentrations be checked prior to treatment, after 1 and 3 months, and every 3 months 
thereafter. If a marked decrease in haemoglobin concentration occurs, further evaluation should be 
undertaken to determine the cause and need for specific treatment.

Excipients
Thelin tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose 
intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this 
medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Sitaxentan sodium is metabolised in the liver by cytochrome P450 CYP2C9 and CYP3A4/5 
isoenzymes. Sitaxentan sodium is an inhibitor of CYP2C9 and, to a lesser extent, CYP2C19, 
CYP3A4/5 and CYP2C8. Plasma concentrations of drugs principally metabolized by CYP2C9 may be 
increased during sitaxentan sodium co-administration. Co-administration with drugs metabolized by 
CYP2C19 or CYP3A4/5 is not expected to result in clinically significant drug interactions. Sitaxentan 
sodium does not affect the p-glycoprotein transporter, but it is postulated to be a substrate of OATP 
transporter proteins.

Effects of other medicinal products on Thelin

Organic Anion Transporting Polypeptides (OATP) Inhibitors: Co-administration with ciclosporin 
A, a potent OATP inhibitor, resulted in a 6-fold increase in Cmin and a 67% increase in AUC of 
sitaxentan therefore the use of Thelin in patients receiving systemic ciclosporin A is contraindicated 
(see section 4.3). Clearance of ciclosporin A was unchanged. 

The extent of interaction with other OATP inhibitors (some HMG CoA reductase inhibitors eg,
atorvastatin, protease inhibitors eg, ritonavir, tuberculostatics eg, rifamycin) is unknown but could 
result in raised plasma levels of sitaxentan. The clinical significance of this is unknown. Patients in 
need of the combination should be closely monitored. Moreover, Clinical interaction studies with 
nelfinavir, a moderately potent OATP inhibitor, and pravastatin, a low affinity OATP inhibitor, did not 
result in clinically significant changes in sitaxentan plasma levels.

Fluconazole (inhibitor of CYP2C19, CYP2C9 and CYP3A4/5): Co-administration of Thelin and 
fluconazole had no effect on the clearance of sitaxentan sodium.

Ketoconazole (substrate and inhibitor of CYP3A4/5): Co-administration with Thelin did not cause a 
clinically significant change in the clearance of either sitaxentan sodium or ketoconazole. 

Nelfinavir (substrate of CYP3A4/5, CYP2C19): Co-administration with Thelin did not cause a 
clinically significant change in the clearance of either sitaxentan sodium or nelfinavir. The clearance 
of nelfinavir was not clinically significantly changed in one subject that was classified as a CYP2C19 
poor metaboliser.

Effects of Thelin on other medicinal products

Warfarin (vitamin K antagonist, substrate of CYP2C9): Concomitant treatment with sitaxentan 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



6

sodium resulted in a 2.4 fold increase in S-warfarin exposure. Subjects receiving warfarin achieve 
therapeutic anticoagulation (International Normalised Ratio [INR] target) with lower doses of the 
anticoagulant in the presence of sitaxentan sodium. It is expected that a similar increase in 
anticoagulant effect will be seen with warfarin analogues, including acenocoumarol, fenprocoumon 
and fluindione. When initiating vitamin K antagonist therapy in a patient taking sitaxentan sodium, it 
is recommended to start at the lowest available dose. In patients already taking a vitamin K antagonist, 
it is recommended that the dose of the vitamin K antagonist be reduced when starting sitaxentan 
sodium. In all cases, INR should be monitored on a regular schedule. Increases in the vitamin K 
antagonist dose should be done in small increments to reach an appropriate target INR. If INR is not 
properly monitored and increased exposure to vitamin K antagonists remains undetected, severe or 
life-threatening bleeding episodes may occur. 

Oral contraceptives (substrate of CYP3A4/5): Concomitant administration of Thelin and Ortho-
Novum 1/35 (1 mg norethindrone/ 0.035 mg ethinyl estradiol) resulted in increases in exposure to 
ethinyl estradiol (substrate of CYP3A4/5) and norethindrone (CYP3A4/5) of 59 % and 47%, 
respectively. However, sitaxentan sodium did not affect the anti-ovulatory activity of the oral 
contraceptive as assessed by the plasma concentrations of follicle stimulating hormone (FSH), 
luteinising hormone (LH), and progesterone (see section 4.4).

Sildenafil (substrate of CYP3A4): A single dose of sildenafil 100 mg coadministered with Thelin 
increased Cmax and AUC∞ of sildenafil by 18% and 28%, respectively. There was no change in Cmax or 
AUC for the active metabolite, n-desmethylsildenafil. These changes in sildenafil plasma 
concentrations were not considered clinically significant. Interaction with sildenafil may be serious if 
hypotension occurs beyond a safe level. Study results suggest that the dose of sildenafil does not need 
to be adjusted during concomitant administration with sitaxentan sodium.

Nifedipine (substrate of CYP3A4/5): The clearance of nifedipine was not clinically significantly 
changed when given concomitantly with Thelin. This was tested for low-dose nifedipine only. 
Therefore, at higher doses of nifedipine, an increase in exposure cannot be excluded. 

Omeprazole (substrate of CYP2C19): Concomitant administration of Thelin with omeprazole 
increased the omeprazole AUC0-24 by 30%; Cmax was unchanged. The change in AUC was not 
considered clinically significant.

Digoxin (substrate of p-Glycoprotein): Concomitant administration of Thelin did not alter the 
pharmacokinetics of digoxin indicating no effect on the p-glycoprotein transporter  

No clinical interaction study was performed with a substrate of CYP 2C8. Therefore an interaction 
with such a drug cannot be excluded.

4.6 Pregnancy and lactation

Pregnancy
There are no human data regarding the use of sitaxentan sodium during pregnancy. Sitaxentan sodium 
caused teratogenicity in rats (see section 5.3). Potential effects in humans are unknown. Thelin should 
not be used during pregnancy unless clearly necessary ie, in case no alternative treatment options are 
available.

Lactation
Sitaxentan sodium was detected in the plasma of breast fed pups from female rats treated with 
sitaxentan sodium, indicating that sitaxentan sodium was present in the breast milk. It is unknown 
whether or not sitaxentan sodium is excreted into human milk. Women should not breastfeed while 
using Thelin.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



7

Women of child-bearing potential
Treatment must not be initiated in women of child-bearing potential unless they practice reliable 
contraception, due to possible teratogenicity. If necessary, pregnancy testing should be undertaken. 

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. A known
undesirable effect is dizziness, which could influence the ability to drive or use machines.

4.8 Undesirable effects

General description 
Safety of Thelin has been evaluated in clinical trials of more than 1200 patients with PAH, as well as 
post-marketing safety data. At the recommended dose during placebo-controlled trials in pulmonary 
arterial hypertension PAH, the most common adverse drug reactions considered to be at least possibly 
related to Thelin treatment were headache in 15% of patients, and peripheral oedema and nasal 
congestion, each in 9% of patients.

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Frequencies are reported as very common ( 1/10), common (> 1/100, < 1/10), uncommon (> 1/1,000,
 1/100), rare (> 1/10,000,  1/1,000), and very rare ( 1/10,000). 

Adverse reactions 

System Organ Class / Adverse reaction Frequency 

Blood and lymphatic system disorders 

Haemoglobin decrease (rarely resulting in anaemia), haematocrit 
decrease 

Uncommon 

Nervous system disorders 

Headache Very common 
Insomnia, dizziness Common 

Vascular disorders 

Gingival bleeding, flushing Common 

Respiratory, thoracic, and mediastinal disorders 

Nasal congestion, epistaxis Common 

Gastrointestinal disorders 

Nausea, constipation, upper abdominal pain, vomiting, dyspepsia and 
diarrhoea 

Common 

Hepatobiliary disorders 

Liver aminotransferases increase, bilirubin increase (associated with 
liver aminotransferase increase) 

Common 

Symptomatic hepatitis Rare 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



8

Skin and subcutaneous tissue 

Rash (various types and presentations) Rare 

Musculoskeletal and connective tissue disorders 

Muscle cramp Common 

General disorders and administration site conditions 

Fatigue, oedema (most commonly peripheral) Common 

Investigations 

INR increase (with concomitant vitamin K antagonist therapy). 
Prothrombin time (PT) increase (with concomitant vitamin K antagonist 
therapy). 

Common 

Increased Liver Aminotransferases (see section 4.4)
Elevations of AST and/or ALT are associated with sitaxentan sodium. In phase 2 and 3 oral studies in 
patients with PAH, elevations in ALT and/or AST > 3 ULN were observed in 5% of placebo-treated 
patients (N = 155) and 7% of Thelin 100 mg-treated patients (N = 887). Elevations in ALT values > 5 
ULN were 4% (36/887) for sitaxentan 100 mg QD and 0.6% in the placebo group (1/155).

The Sitaxentan population also included patients (N = 53) who had discontinued another endothelin 
receptor antagonist due to liver function abnormalities.  This specific group had a higher risk (19%;  
N = 10/53) of developing elevations in ALT and/or AST > 3 x ULN indicating that appropriate care 
should be exercised when initiating sitaxentan in this patient population.

Decreased Haemoglobin (see section 4.4)
The overall mean decrease in haemoglobin concentration for Thelin -treated patients was 0.5 g/dl 
(change to end of treatment). In placebo-controlled studies, marked decreases in haemoglobin (> 15% 
decrease from baseline with value < lower limit of normal) were observed in 7% of patients treated 
with Thelin (N = 149) and 3% of placebo-treated patients (N = 155). A decrease in haemoglobin 
concentration by at least 1 g/dl was observed in 60% of patients treated with Thelin as compared to 
32% of placebo-treated patients.

Post marketing experience
Adverse events reported during the post-marketing period to date have been similar to those reported 
in clinical trials. Cases of concurrent elevations of transaminases (ALT and/or AST) > 8 x ULN and 
total bilirubin > 2 x ULN have been reported following administration of sitaxentan sodium.  This may 
lead to hepatic failure, which can be fatal, and highlights the need for regular monitoring of 
transaminases and bilirubin.

4.9 Overdose

There is no specific experience with the management of Thelin overdose. In the event of overdose, 
symptomatic and supportive measures should be employed.

During clinical trials, Thelin was given as a daily oral dose of 1000 mg/day for 7 days to healthy 
volunteers. The most common adverse effects at this dose were headache, nausea, and vomiting.

In an open-label hypertension study, 10 patients received 480 mg twice daily (approximately a 10-fold 
increase in daily dose compared to the MRHD) for up to 2 weeks. Headaches (some severe), 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



9

peripheral oedema, and anaemias were the most common adverse events reported in these patients, 
none of which were considered serious.

In an open-label PAH study, one fatal case of hepatic failure has been reported after chronic dosing of 
sitaxentan at 600 mg/day administered as 300 mg bid.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other antihypertensives, ATC code: C02KX03

Mechanism of action
Endothelin-1 (ET-1) is a potent vascular paracrine and autocrine peptide in the lung, and can also 
promote fibrosis, cell proliferation, cardiac hypertrophy, and remodelling and is pro-inflammatory. 
ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial 
hypertension (PAH), as well as other cardiovascular disorders and connective tissue diseases, 
including scleroderma, acute and chronic heart failure, myocardial ischaemia, systemic hypertension, 
and atherosclerosis, suggesting a pathogenic role of ET-1 in these diseases. In PAH and heart failure, 
in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated 
with the severity and prognosis of these diseases. Additionally, PAH also is characterized by reduced 
nitric oxide activity.

ET-1 actions are mediated through endothelin A receptors (ETA), present on smooth muscle cells, and 
endothelin B receptors (ETB), present on endothelial cells. Predominant actions of ET-1 binding to 
ETA are vasoconstriction and vascular remodelling, while binding to ETB results in ET-1 clearance, 
and vasodilatory/ antiproliferative effects due in part to nitric oxide and prostacyclin release.

Thelin is a potent (Ki 0.43 nM) and highly selective ETA antagonist (approximately 6,500-fold more 
selective for ETA as compared to ETB).

Efficacy
Two randomized, double-blind, multi-centre, placebo-controlled trials were conducted to demonstrate 
efficacy. STRIDE-1, which included 178 patients, compared 2 oral doses of Thelin (100 mg once daily 
and 300 mg once daily) with placebo during 12 weeks of treatment. The 18 week STRIDE-2 trial, 
conducted in 246 patients, included 4 treatment arms: placebo once daily, Thelin 50 mg once daily, 
Thelin 100 mg once daily, and open-label bosentan twice daily (efficacy-rater blinded, administered 
according to the approved package insert).

STRIDE-4 included 98 patients randomised to sitaxentan sodium 50 mg, 100 mg, and placebo once 
daily for 18 weeks. Efficacy endpoints included sub maximal exercise capacity, WHO functional 
class and Time to Clinical Worsening for all studies, and haemodynamics for STRIDE-1.

Patients had moderate to severe (NYHA/WHO functional class II-IV) PAH resulting from idiopathic 
pulmonary arterial hypertension (IPAH, also known as primary pulmonary hypertension), connective 
tissue disease (CTD), or congenital heart disease (CHD).

In these studies, the study medicine was added to patients’ current therapy, which could have included 
a combination of digoxin, anticoagulants, diuretics, oxygen, and vasodilators (eg, calcium channel 
blockers, ACE inhibitors). Patients with pre-existent hepatic disease and patients using non-
conventional PAH treatments (eg, iloprost) were excluded.

Sub-maximal exercise capacity: This was assessed by measuring distance walked in 6 minutes 
(6-minute walk test) at 12 weeks for STRIDE-1 and 18 weeks for STRIDE-2 and STRIDE-4. In both 
STRIDE-1 and STRIDE-2 trials, treatment with Thelin resulted in a significant increase in exercise 
capacity. The placebo-corrected increases in walk distance in the whole cohort compared to baseline 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



10

were 35 metres (p = 0.006; ANCOVA) and 31 metres (p < 0.05; ANCOVA), respectively. In 
STRIDE-4, a statistically non-significant placebo-corrected mean improvement of 24.3 metres (p = 
0.2078) was observed in the whole cohort. Among patients with PAH associated with CTD in 
STRIDE-1 and STRIDE-2, a statistically significant difference versus placebo was observed 
(37.73 metres, p < 0.05).

Haemodynamic parameters: These were assessed in STRIDE-1 for both functional class II and III 
patients. Compared with placebo treatment, Thelin resulted in statistically significant improvement in 
pulmonary vascular resistance (PVR) and cardiac index (CI) after 12 weeks of treatment (see below). 

Treatment Comparison of Change from Baseline in PVR, and CI at Week 12 by 
Functional Class – STRIDE 1: Sitaxentan 100 mg Versus Placebo

Functional Class Median Difference from Placebo (95% CI) P-Value
PVR (dyne*sec/cm5)

II -124 (-222.7, -17.8) 0.032
III -241.2 (-364.6, -136.4) < 0.001

CI (L/min/m2)
II 0.5 (0.2, 0.8) 0.003
III 0.3 (0.1, 0.5) 0.015

Systemic vascular resistance (-276 dynes*sec/cm5 (16%)) was improved after 12 weeks of treatment.  
The reduction in mean pulmonary artery pressure of 3 mmHg (6%) was not statistically significant.

The effect of Thelin on the outcome of the disease is unknown.  

Functional Class: A reduction in symptoms of PAH were observed with sitaxentan sodium 100 mg 
treatment. Improvements in functional class were observed across all studies (STRIDE-1, STRIDE-2 
& STRIDE-4). 

Long-term survival:There are no randomised studies to demonstrate beneficial effects on survival of 
treatment with sitaxentan sodium. However, patients completing STRIDE-2 were eligible to enrol in 
open-label studies (STRIDE-2X and STRIDE-3). A total of 145 patients were treated with sitaxentan 
sodium 100 mg and their long term survival status was assessed for a minimum of 3 years. In this total 
population, Kaplan-Meier estimates of 1, 2 and 3 year survival were 96%, 85% and 78% respectively.
These survival estimates were similar in the subgroup of patients with PAH associated with CTD for 
the Thelin treated group (98%, 78% and 67% respectively). The estimates may have been influenced 
by the initiation of new or additional PAH therapies, which occurred in 24% of patients at one year. 

5.2 Pharmacokinetic properties

Absorption 
Sitaxentan sodium is rapidly absorbed following oral administration. In PAH patients, peak plasma 
concentrations are generally achieved within 1-4 hours. The absolute bioavailability of Thelin is 
between 70 and 100%.  When administered with a high fat meal, the rate of absorption (Cmax) of 
Thelin was decreased by 43% and the Tmax delayed (2-fold increase) compared to fasted conditions, 
but the extent of absorption was the same.

Distribution
Sitaxentan sodium is more than 99% protein bound to plasma proteins, predominantly albumin. The 
degree of binding is independent of concentration in the clinically relevant range. Sitaxentan sodium 
does not penetrate into erythrocytes and does not appear to cross the blood-brain barrier.

Metabolism and Elimination
Following oral administration to healthy volunteers, sitaxentan sodium is highly metabolised. The 
most common metabolic products are at least 10 times less potent as ETA antagonists than sitaxentan 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



11

sodium in a standard in vitro test of activity. In vitro, sitaxentan sodium is metabolized by CYP2C9 
and CYP3A4/5. 

In vitro studies using human liver microsomes or primary hepatocytes show that sitaxentan sodium 
inhibits CYP2C9, and, to a lesser extent, CYP 2C8, CYP2C19 and CYP3A4/5. 

Approximately 50-60% of an oral dose is excreted in the urine with the remainder eliminated in the 
faeces. Less than 1% of the dose is excreted as unchanged active ingredient. The terminal elimination 
half-life (t½) is 10 hours. Steady state in volunteers is reached within about 6 days.

No unexpected accumulation in the plasma was observed after multiple dosing at the recommended 
dose of 100 mg once daily. However, at doses of 300 mg or higher, non-linear pharmacokinetics result 
in disproportionately higher plasma concentrations of sitaxentan sodium. 

Special Populations
Based on results of the population pharmacokinetic analysis and pooled pharmacokinetic data over 
several studies, it was found that gender, race, and age do not clinically significantly affect the 
pharmacokinetics of sitaxentan sodium.

Liver Function Impairment 
The influence of liver impairment on the pharmacokinetics of sitaxentan sodium has not been 
evaluated. Refer to section 4.3. 

5.3 Preclinical safety data

In repeated-dose toxicity studies, dose-related liver changes (weight, centrilobular hypertrophy, 
occasionally necrosis), induction of hepatic drug metabolising enzymes and slightly decreased 
erythron parameters were seen in mice, rats and dogs. At high doses, dose-related increases in 
prothrombin time (PT) and activated partial thromboplastin time (APTT) were also seen, most 
prominently in rats, and coagulopathy (bleedings) in rats and dogs, but not mice. The significance of 
these findings for humans is unknown.

Testicular tubular atrophy was observed in rats, but not in mice or dogs.  In the 26-week study, 
moderate to marked diffuse seminiferous tubular atrophy was present at a very low incidence, whereas 
in the 99-week study there was a dose-related, slightly increased incidence of minimal to mild focal 
atrophy at doses providing 29 to 94 times the human exposure. 

Reproduction toxicity has been evaluated in rats only. Thelin did not affect fertility in males and 
females. Thelin was teratogenic at the lowest tested dose in rats, corresponding to exposures more than 
30 times the human exposure. Dose-dependent malformations of the head, mouth, face and large blood 
vessels occurred. A NOAEL has not been established.

Administration of Thelin to female rats from late-pregnancy through lactation reduced pup survival, 
and caused testis tubular aplasia and delayed vaginal opening at the lowest exposure tested (17-45 
times the human exposure). Large / abnormally shaped livers, a delay in auditory function 
development, a delay in preputial separation and a reduction in the number of embryonic implants 
occurred at higher maternal doses.

In vitro and in vivo tests on genetic toxicology did not provide any evidence for a clinically relevant 
genotoxic potential.

Thelin was not carcinogenic when administered to rats for 97-99 weeks or when administered to 
p53(+/-) transgenic mice for 6 months.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



12

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:
Cellulose, microcrystalline (E460)
Lactose monohydrate
Hypromellose (E464)
Sodium starch glycolate
Magnesium stearate (E470b)
Disodium phosphate, anhydrous (E339)
Ascorbyl palmitate (E304)
Disodium edetate
Monobasic sodium phosphate (E339)

Film coat:
Stearic acid (E570b)
Hypromellose (E464)
Cellulose, microcrystalline (E460)
Titanium dioxide (E171)
Yellow iron oxide dehydrate (E172)
Red iron oxide dehydrate (E172)
Talc (E553b)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

PVC/ACLAR/paper-backed aluminium blisters containing 14 tablets.
Cartons contain 14, 28, 56, or 84 tablets.
High-density polyethylene (HDPE) bottles containing 28 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Pfizer Limited
Sandwich,
Kent, CT13 9NJ,
United Kingdom

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



13

8. MARKETING AUTHORISATION NUMBER(S) 

EU/1/06/353/001 
EU/1/06/353/002 
EU/1/06/353/003 
EU/1/06/353/004 
EU/1/06/353/005 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10 August 2006

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicine is available on the European Medicines Agency  web site: 
http://www.ema.europa.eu/.  There are also links to other websites about rare diseases and treatments.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



14

ANNEX II

A. MANUFACTURING AUTHORISATION HOLDER 
RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORISATION

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



15

A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH 
RELEASE

Name and address of the manufacturers responsible for batch release

Pfizer Service Company
Hoge Wei 10
B-1930
Zaventem
Belgium

The printed package leaflet of the medicinal product must state the name and address of the 
manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OF THE MARKETING AUTHORISATION

 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON 
THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to restricted medical prescription. (See Annex I: Summary of Product
Characteristics, section 4.2)

 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT

The MAH shall set up a surveillance programme to collect information on: the demographics of 
patients prescribed Thelin, any adverse reactions and reasons for discontinuation of Thelin. Details of 
such a surveillance programme should be agreed with the National Competent Authorities in each 
member state and put in place prior to marketing of the product.

The MAH must agree the details of a controlled distribution system with the National Competent 
Authorities and must implement such programme nationally to ensure that, prior to prescribing, all 
doctors who intend to prescribe Thelin are provided with a physician information pack containing the 
following:
 Product information
 Physician information about Thelin
 Patient information card
 Partner of patient information card

The physician information about Thelin should contain the following key elements:
 That Thelin is teratogenic

o Use of effective contraception in women of child bearing age
o Possible interaction with oral contraceptives and increased risk of thromboembolism
o Need to advise female patients about teratogenicity, contraception, if necessary the need 

for pregnancy testing and what to do if they become pregnant
o Referral of patients who become pregnant to a physician specialised or experienced in 

teratology and its diagnosis for evaluation and advice

 That Thelin is hepatotoxic
o Need for liver function tests prior to and during treatment
o Contraindication in patients with pre-existing hepatic impairment (Child-Pugh Class A-C).
o Contraindication in patients with elevated direct bilirubin  > 2 x ULN prior to initiation of 

treatment.
o Need for close monitoring if liver enzymes measure > 3  × upper limit normal (ULN):

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



16

 > 3 and ≤ 5 x ULN: Confirm by another liver test;if confirmed, a decision should 
be made on an individual basis to continue or to stop Thelin administration.  
Continue to monitor aminotransferases at least every 2 weeks.  If the 
aminotransferase levels return to pre-treatment values consider resuming the 
initial treatment schedule.

 > 5 and ≤ 8 x ULN: Confirm by another liver test; if confirmed, stop treatment 
and monitor aminotransferase levels at least every 2 weeks until levels have 
normalised.  If the aminotransferase levels return to pre-treatment values, 
reintroducing Thelin may be considered.

 > 8 x ULN: treatment must be stopped and reintroduction of Thelin is not to be 
considered. 

 That treatment with Thelin often causes a decrease in haemoglobin and related red cell parameters
o Need for full blood count prior to use and monitoring at clinically appropriate intervals

 Effect of Thelin on bleeding
o Interaction with warfarin and vitamin K antagonists leading to an increased INR
o Need to decrease established dose of vitamin K antagonist upon starting sitaxentan 

therapy
o Start vitamin K antagonists treatment at a reduced dose if already on sitaxentan sodium
o Need for regular monitoring of INR
o Be aware of the potential for haemorrhage and investigate as appropriate
o Increased risk of epistaxis and gingival bleeding

 That there is an interaction with ciclosporin A which may lead to higher blood concentration of 
Thelin and hence an increased risk of adverse reactions.

 That the safety database of Thelin is limited and physicians are encouraged to enrol patients in a 
surveillance programme to increase knowledge about the incidence of important adverse drug 
reactions (ADRs). The surveillance programme should prompt doctors to report serious ADRs and 
certain selected ADRs as below immediately and other non-serious ADRs at three monthly 
intervals. 

The information collected should include:
o Anonymised patient details – age, sex and aetiology of PAH
o Concomitant medications
o Reason for discontinuation
o ADRs
o All serious ADRs
o Increase in hepatic enzymes to > 3 × ULN
o Elevated direct bilirubin > 2 ×ULN
o Anaemia
o Haemorrhage
o Pregnancy and outcome
o Pulmonary oedema (associated with veno-occlusive disease)
o Suspected interactions
o Unexpected ADRs according to the SPC.

The Patient information card should include the following information
 That Thelin is teratogenic
 The need to ensure that women of child bearing age are using effective contraception and that 

patients should inform their doctors of any possibility of pregnancy before a new prescription is 
issued

 The need for female patients to contact their treating doctor immediately if they suspect that they 
might be pregnant.

 That Thelin is hepatotoxic and they will need to attend for regular blood tests
 The need to tell their doctor about any adverse events

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



17

 The need to tell their doctor that they are taking Thelin

Partner of patient information card should include the following information:
 That Thelin is teratogenic and that women of child bearing age must use effective contraception

OTHER CONDITIONS

Pharmacovigilance system
The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in 
Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and 
whilst the product is on the market.

Risk Management Plan
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in 
the Pharmacovigilance Plan, as agreed in version 5 of the Risk Management Plan (RMP) presented in 
Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP 
agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the 
updated RMP should be submitted at the same time as the next Periodic Safety Update Report 
(PSUR).

In addition, an updated RMP should be submitted
 When new information is received that may impact on the current Safety Specification, 

Pharmacovigilance Plan or risk minimisation activities
 Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being 

reached
 At the request of the European Medicines Agency.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



18

ANNEX III

LABELLING AND PACKAGE LEAFLET

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



19

A. LABELLING

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



20

PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE 
PACKAGING

Blister Carton

1. NAME OF THE MEDICINAL PRODUCT

Thelin 100 mg film-coated tablets
Sitaxentan sodium 

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 100 mg of sitaxentan sodium

3. LIST OF EXCIPIENTS

Contains lactose monohydrate 

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets in blisters
28 film-coated tablets in blisters
56 film-coated tablets in blisters
84 film-coated tablets in blisters

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP:  {MM/YYYY}

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



21

9. SPECIAL STORAGE CONDITIONS

Store below 25°C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Pfizer Limited
Sandwich,
Kent, CT13 9NJ,
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/06/353/001 (14 film-coated tablets in blisters)
EU/1/06/353/002 (28 film-coated tablets in blisters)
EU/1/06/353/003 (56 film-coated tablets in blisters)
EU/1/06/353/004 (84 film-coated tablets in blisters)

13. BATCH NUMBER

Lot: {number}

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Sitaxentan

To be written in braille at time of manufacture.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



22

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

PVC/ACLAR/paper-backed aluminium blisters

1. NAME OF THE MEDICINAL PRODUCT

Thelin 100 mg film-coated tablets
Sitaxentan sodium

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Pfizer Limited

3. EXPIRY DATE

EXP: {MM/YYYY}

4. BATCH NUMBER

Lot: {number}

5. OTHER

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



23

PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE 
PACKAGING

Bottle Label (fix-a form)

1. NAME OF THE MEDICINAL PRODUCT

Thelin 100 mg film-coated tablets
Sitaxentan sodium

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 100 mg of sitaxentan sodium

3. LIST OF EXCIPIENTS

Conatains lactose monohydrate 

4. PHARMACEUTICAL FORM AND CONTENTS

28 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP: {MM/YYYY}

9. SPECIAL STORAGE CONDITIONS

Store below 25°C.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



24

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Pfizer Limited
Sandwich,
Kent, CT13 9NJ,
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/06/353/005

13. BATCH NUMBER

Lot:

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Sitaxentan

To be written in braille at time of manufacture.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



25

B. PACKAGE LEAFLET 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



26

PACKAGE LEAFLET: INFORMATION FOR THE USER

Thelin 100 mg film-coated tablets
Sitaxentan sodium

Read all of this leaflet carefully before you start taking this medicine.
 Keep this leaflet.  You may need to read it again.
 If you have any further questions, ask your doctor or pharmacist.
 This medicine has been prescribed for you.  Do not pass it on to others.  It may harm them, even 

if their symptoms are the same as yours.
 If any side effect becomes serious, or if you notice any side effects not listed in this leaflet, 

please tell your doctor or pharmacist.

In this leaflet:
1. What Thelin is and what it is used for
2. Before you take Thelin
3. How to take Thelin
4. Possible side effects
5. How to store Thelin
6. Further information

1. WHAT THELIN IS AND WHAT IT IS USED FOR

Thelin is used to help lower blood pressure in the blood vessels when this pressure is raised in 
pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is the term used when the 
heart struggles to pump blood to the lungs.  Thelin lowers the blood pressure by widening these 
vessels, so your heart can pump blood more effectively.  This will make it easier for you to do more 
activities.

2. BEFORE YOU TAKE THELIN

Do not take Thelin:
 If you are allergic (hypersensitive) to sitaxentan sodium or any of the other ingredients in these 

tablets;
 If you have or have had a serious liver problem;
 If you have raised levels of some liver enzymes (detected by blood tests);
 If you are taking Ciclosporin A (used to treat psoriasis and rheumatoid arthritis, and to prevent 

rejection of liver or kidney transplants);
 If you are breast-feeding (please read the section ‘Pregnancy and breast-feeding’ below);
 If you are a child or adolescent under 18 years old.

Take special care with Thelin:
 If you could get pregnant or are pregnant (please read the section “Pregnancy and breast-feeding” 

below);
 If you develop liver problems or symptoms that might relate to the liver (see ‘Testing for liver 

problems’, below);
 If you are taking or begin to take anticoagulants (e.g. warfarin, acenocoumarol, fenprocoumon 

or fluindione) to prevent blood clots.  The dose of these medicines may need to be adjusted by 
your doctor.

 If you are taking a statin (e.g. pravastatin or simvastatin).
 If you are taking a high dose of nifedipine.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



27

If any of these apply to you, tell your doctor before you start taking Thelin.

The following two blood tests will be carried out before you first take Thelin and at intervals during 
treatment 

Testing for liver problems
Thelin may affect your liver.  Your doctor will take blood tests to check that your liver is working 
properly, before and during treatment with Sitaxentan sodium.  It is important to have these tests every 
month during treatment, even if you do not have any symptoms at all.

If you notice any of these signs:
 feeling sick (nausea)
 being sick (vomiting)
 loss of appetite
 fever
 unusual tiredness
 pain in the stomach (abdominal pain)
 yellow colouring of the skin and eyes (jaundice)
Talk to your doctor immediately.  These may be signs that your liver is not working properly.

Testing for anaemia
This blood test will be done before treatment, then one month and three months after you start taking 
Thelin tablets.  Following this, the test will continue to be done every three months to check for 
anaemia (a reduced amount of red blood cells).

For your own safety, it is very important that you have regular blood tests.

Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines.  
This includes medicines you bought without a prescription, herbal remedies and vitamins.  

These medicines may interfere with the effect of Thelin.

Do not take Thelin if you are taking Ciclosporin A.

Thelin should be used with caution if you are taking or begin to take Vitamin K antagonists (e.g. 
warfarin, acenocoumarol, fenprocoumon or fluindione).

Driving and using machines
Do not drive or use any tools or machines if you feel dizzy.

Pregnancy and breast-feeding
If you are able to get pregnant, you must use effective contraception while taking Thelin. Your doctor 
will advise you about suitable contraception. Your doctor may recommend monthly pregnancy tests 
while you are taking Thelin. 

If you miss a period or think you may be pregnant, contact your doctor right away. He or she may 
want you to stop taking Thelin. Tell your doctor at once if you are or plan to become pregnant in 
the near future.

Do not breast-feed if you are taking this medicine, it is not known if it passes into breast milk.

Important information about some of the ingredients of Thelin
Thelin tablets contain lactose monohydrate.  If you are intolerant to some sugars, contact your doctor 
before taking Thelin tablets.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



28

3. HOW TO TAKE THELIN

The usual dose is a 100 mg tablet once a day.
Always take Thelin exactly as your doctor has told you.  Check with your doctor or pharmacist if you 
are not sure.
 Try to take the tablet at the same time each day to help you remember.  Swallow the tablet 

whole with water.  It does not matter whether you take it with or without food.

Do not take more than one tablet each day.  You may need to take Thelin for a month or two before 
feeling any effect.

If you take more Thelin than you should
If you realise you have taken more Thelin tablets than your doctor has recommended (or if someone 
else has taken some of your Thelin tablets), contact your doctor straight away.  If you cannot reach 
your doctor, go to the nearest hospital and take the pack with you.

If you forget to take Thelin
If you miss a dose, take the missed dose as soon as you remember but do not take two tablets in one 
day.

If you stop taking Thelin
Talk to your doctor before stopping treatment.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Thelin can cause side effects, although not everybody gets them.

Very common side effects (likely to affect more than 1 in 10 patients):
 headache

Common side effects (likely to affect more than 1 in every 100 people):
 swelling in the arms and legs
 being unable to sleep
 blocked nose and nosebleeds
 bleeding from the gums
 feeling and/or being sick, difficulty in passing stools, stomach ache, indigestion and diarrhoea
 flushed
 cramp in muscles
 dizziness
 feeling tired
 your blood may take longer to clot.
 yellowing of the skin or eyes ( jaundice) and persistent nausea and/or vomiting may indicate  

changes in liver function 

Rare side effects (likely to affect less than 1 in 1000 people):
 Liver damage
 Rash
 Anaemia (low blood count) 

For more details on liver problems, see ‘Testing for liver problems’ in section 2.

If any of the side effects become serious, or if you notice any other side effects not listed in this leaflet, 
please tell your doctor or pharmacist.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



29

5. HOW TO STORE THELIN

Keep out of the reach and sight of children.

Do not use Thelin after the expiry date which is stated on the blister pack, bottle or carton after EXP.  
The expiry date refers to the last day of that month.

Do not store above 25°C.

Medicines should not be disposed of via wastewater or household waste.  Ask your pharmacist how to 
dispose of medicines you no longer require.  These measures will help to protect the environment.

6. FURTHER INFORMATION

What Thelin contains
 The active substance is sitaxentan sodium.
The other ingredients are:
 The tablet core contains cellulose, microcrystalline (E460), lactose monohydrate, hypromellose 

(E464), sodium starch glycolate, magnesium stearate (E470b), anhydrous disodium phosphate 
(E339), ascorbyl palmitate (E304), disodium edetate and monobasic sodium phosphate (E339).

 The film-coat contains stearic acid (E570b), hypromellose (E464), microcrystalline cellulose 
(E460), titanium dioxide (E171), yellow iron oxide dehydrate (E172), red iron oxide dehydrate 
(E172) and talc (E553b).

What Thelin tablets look like and contents of the pack
Thelin 100 mg film-coated tablets are yellow-to-orange, capsule-shaped tablets, marked with T-100 on 
one side.
Thelin comes in blister packs of 14, 28, 56, and 84 tablets and bottles of 28 tablets.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing authorisation holder:
Pfizer Limited
Sandwich,
Kent, CT13 9NJ,
United Kingdom

Manufacturer:

Pfizer Service Company
Hoge Wei 10
B-1930
Zaventem
Belgium

For any information about this medicinal product, please contact the local representative of the 
Marketing Authorisation Holder:

België /Belgique / Belgien Luxembourg/Luxemburg
Pfizer S.A./N.V. Pfizer S.A.
Tél/Tel: +32 (0)2 554 62 11 Tél/Tel: +32 (0)2 554 62 11

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



30

България Magyarország
Пфайзер Люксембург САРЛ, Клон България Pfizer Kft.
Тел.: +359 2 970 4333 Tel.: + 36 1 488 37 00

Česká republika Malta
Pfizer s.r.o. V.J. Salomone Pharma Ltd.
Tel: +420-283-004-111 Tel : + 356 21 22 01 74

Danmark Nederland

Pfizer ApS Pfizer bv
Tlf: +45 44 20 11 00 Tel: +31 (0)10 406 43 01

Deutschland Norge
Pfizer Pharma GmbH Pfizer AS
Tel: +49 (0)30 550055 51000 Tlf: +47 67 52 61 00

Eesti Österreich
Pfizer Luxembourg SARL Eesti filiaal Pfizer Corporation Austria Ges.m.b.H.
Tel: +372 6 405 328 Tel: +43 (0)1 521 15-0

Ελλάδα Polska
Pfizer Hellas A.E. Pfizer Polska Sp. z o.o.,
Τηλ:   +30 210 678 5800 Tel.: +48 22 335 61 00

España Portugal
Pfizer S.A. Laboratórios Pfizer, Lda.
Tel: +34 91 490 99 00 Tel: +351 21 423 5500

France România
Pfizer Pfizer România S.R.L.
Tél: +33 (0)1 58 07 34 40 Tel: +40 21 207 28 00

Ireland Slovenija
Pfizer Healthcare Ireland Pfizer Luxembourg SARL

Pfizer, podružnica za svetovanje s področja 
farmacevtske dejavnosti, Ljubljana

Tel: 1800 633 363 (toll free) Tel: + 386 (0) 1 52 11 400
+44 (0)1304 616161

Ísland Slovenská republika
Vistor hf. Pfizer Luxembourg SARL, organizačná zložka
Sími: + 354 535 7000 Tel: +421-2-3355 5500

Italia Suomi/Finland
Pfizer Italia S.r.l. Pfizer Oy
Tel: +39 06 33 18 21 Puh/Tel: +358 (0)9 43 00 40

Κύπρος Sverige 
GEO. PAVLIDES & ARAOUZOS LTD, Pfizer AB
Τηλ: +35722818087 Tel:  + 46 (0)8 550 520 00

Latvija United Kingdom

Pfizer Luxembourg SARL filiāle Latvijā Pfizer Limited
Tel: +371 670 35 775 Tel: +44 (0)1304 616161

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



31

Lietuva
Pfizer Luxembourg SARL filialas Lietuvoje
Tel. +3705 2514000

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu/.  There are also links to other websites about rare diseases and treatments. 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OF THE MARKETING AUTHORISATION
	A. LABELLING
	B. PACKAGE LEAFLET